Optimal delivery to ensure effective treatment of cancer and more

Fenix Therapeutics aims to reshape cancer outcomes, providing hope to patients by transforming the future of oncology through more specific and effective treatments.

Personalized targeted treatment selection for metastatic cancer patients through full blood volume tumor cell analysis.

Gateway Bio solves antimicrobial resistance. Our proprietary nanocarrier transports antibiotic payloads inside bacterial cells, bypassing resistance mechanisms. The platform is compound-agnostic, compatible with existing and pipeline antibiotics, and its modular design enables partners to generate patent protection across successive lifecycle stages. Our proprietary production process ensures scalability at low cost, a critical differentiator in this market.

Gemini Theranostics developed a theranostic platform targeting the Follicle Stimulating Hormone Receptor (FSHR), a therapeutic target that is expressed in 50-70% of ovarian cancer patients.

Next-generation gene promoters for more stable and higher recombinant protein expression.

Pionering whole genome sequencing based genotoxicity testing

GlycoDiagnostics developed a novel, non-invasive diagnostic test based on a glycan biomarker that enables early and accurate detection of fibrosis. The GlycoDiagnostics test leverages specific glycosylation signatures that outperform existing tests such as FIB-4 and FibroScan in a proof-of-concept retrospective clinical study. It enables more reliable and effective patient identification for clinical trials, reducing missed cases, accelerating recruitment, and lowering costs. The test is minimally invasive, compatible with plasma or dried blood spots, and scalable for multicenter trials.

A robust patient monitoring device which is highly reliable and easy to use to prevent children in low and middle income countries unnecessary dying from severe bacterial infections.

HeartSmart revolutionizes cardiac research with a miniaturized heart tissue model that accurately mimics fibrosis and enables reliable, predictive drug testing for heart failure therapies.